Loading...
Found 74 Muscular Dystrophy trials
A listing of Muscular Dystrophy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This study will involve patients with high risk non-muscle invasive bladder cancer (NMIBC) that is persistent (cancer stays) or recurrent (cancer comes back) following Bacillus Calmette-Guérin BCG treatment. The purpose of this study is to: o Test the safety of the study drugs, pembrolizumab in combination with Bacillus Calmette-Guerin (BCG) …
Please see section 1 of protocol
Please see section 1 of protocol
The purpose of this study is to determine if a particular Magnetic Resonance Imaging (MRI) called Diffusion Weighted (dwMRI)) will detect changes in your tumor before and during treatment with chemotherapy and radiation for esophageal cancer. We used the dwMRI because it has been used in other types of cancers …
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
To confirm the efficacy of OTL38 in combination with fluorescent light to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions
This study investigates the effects of adding cytoreductive radical prostatectomy (CRP) to the standard treatment, best systemic therapy (BST), for metastatic prostate cancer (mPCa). CRP removes as much of the cancer as possible (and radical prostatectomy removes only prostate) while BST uses drugs toxic to cancer cells: chemotherapy and androgen …
Please see attached protocol.
A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment …
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
Please choose between Voice or SMS based delivery of verification code
or